Outcomes of locally advanced prostate cancer: A single institution study of 209 patients in Japan

Asian Journal of Andrology

Volumn 8, Issue 5, 2006, Pages 555-561

  Saito, Toshihiro ^a   Kitamura, Yasuo ^a   Komatsubara, Shuichi ^a   Matsumoto, Yasuo ^a   Sugita, Tadashi ^a   Hara, Noboru ^a,b  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Hormone therapy; Locally advanced prostate cancer; Radical prostatectomy; Radio therapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; FLUTAMIDE; FOSFESTROL; GOSERELIN; LEUPRORELIN;

ADULT; ADVANCED CANCER; AGED; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HEMATURIA; HUMAN; INTERMETHOD COMPARISON; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECTUM DISEASE; RECTUM HEMORRHAGE; RECTUM INJURY; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TIME SERIES ANALYSIS; TREATMENT OUTCOME; URETHRA STRICTURE; URINE INCONTINENCE;

AGED; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747615264     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2006.00175.x     Document Type: Review

References (22)

1. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
2. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168: 2016-9.
3. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6.
4. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46.
5. Akaza H. Advanced prostate cancer treatment guidelines: A global perspective; trends of hormone therapy in Japan. BJU Int 2004; 94(Suppl 3): 5.
6. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN, Yatani R. Comparative studies of prostate cancer in Japan versus the United States. Urol Oncol 2000; 5: 274-83.
7. Fukagai T, Shimada M, Yoshida H, Namiki T, Carlile RG. Clinical-pathological comparison of clinical prostate cancer between Japanese Americans in Hawaii and Japanese living in Japan. Int J Androl 2000; 23(Suppl 2): 43-4.
8. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62: 140-7.
9. Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: Value for the staging of prostate cancer. Clin Cancer Res 2002; 8: 1794-9.
10. Arai Y. Radical prostatectomy: Time trends, morbidity and quality of life. Int J Urol 2001; 8: S15-8.
11. Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 2005; 41: 908-21.
12. Eulau SM, Corn BW. Combinations of hormones and local therapies in locally advanced prostate carcinoma. Oncology 1996; 10: 1193-202.
13. Hachiya T, Akakura K, Saito S, Shinohara N, Sato K, Harada M, et al. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. BJU Int 2005; 95: 534-40.
14. Fowler, JE Jr, Bigler, SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J Urol 2002; 168: 546-9.
15. Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: Radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999; 54: 313-8.
16. Yan SX, Ejima Y, Sasaki R, Zheng SS, Demizu Y, Soejima T, et al. Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells. Asian J Androl 2004; 6: 285-90.
17. Mottet N. Hormonal treatment alone for locally advanced prostate cancer. BJU Int 2004; 94 (Suppl 3): 14-5.
18. Akaza H, Homma Y, Okada K, Yokoyama M, Usami M, Hirao Y, et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: Results of the 5-year follow-up. BJU Int 2003; 91: 33-6.
19. Peters N, Armstrong K. Racial differences in prostate cancer treatment outcomes: A systematic review. Cancer Nurs 2005; 28: 108-18.
20. Fukagai T, Morita M, Yoshida H, Namiki T, Carliele R. The racial differences of prognosis after hormone treatment for prostate cancer. Jpn J Urol Surg 2004; 17: 955-7.
21. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison. J Urol 1999; 161: 1223-7.
22. Qian LX, Hua LX, Wu HF, Sui YG, Cheng SG, Zhang W, et al. Anemia in patients on combined androgen block therapy for prostate cancer. Asian J Androl 2004; 6: 383-4.